



NWR Virtual Healthcare Conference

Redefining Medicine



World's Fastest Growing Pharmaceutical Manufacturer of
Cannabis | Psilocybin | MDMA

Innovative medicines for patients with unmet clinical needs

\$4 BILLION+ / YEAR DEMAND

Mental health + chronic conditions = growing unmet need (\$100bn+/year)

Rapid adoption of psychedelic therapies & cannabis (\$4bn+ / year patients buying medicinal cannabis in Australia, UK, Germany, EU)

Manufacturing capacity – overcoming bottleneck

REGULATORY BARRIERS

Highly regulated market with strict licensing and controls = significant barriers to entry

Restricted supply – there are only a handful of licensed manufacturers cannabis

BXN is the only company licensed to manufacture cannabis, MDMA, and psilocybin medicines

H1 FY2026 Overview



Record half driven by sustained demand for GMP-manufactured medicinal cannabis, MDMA and psilocybin products

\$31.3m

Revenue

+149% pcp

\$7.3m

NPAT

+121% pcp

\$8.3m

Adjusted EBITDA

+137% pcp

\$7.6m

Cash on Hand

\$20m

Net Assets

+\$8m

Revenue Per month

EBITDA UPGRADE

FY26 Adjusted EBITDA Guidance


\$16.5m – \$19m up from \$11.5 - \$13.5m

FY26 Revenue Guidance

\$65m – \$75m


We're not just growing — we're scaling profitably

Pharmaceutical Supply Chain –Doing what others don't / cannot do



Bioxyne - TGA, GMP Licenced Pharmaceutical Manufacturer of novel therapeutic medicines with national & international distribution.

Bioxyne - market leading manufacturer with >\$250m /year capacity



Integrated Pharmaceutical Manufacturing Platform

- Licensed by TGA, QLD Health and ODC
- GMP-certified manufacturing capability
- Importer and exporter of medicinal cannabis, psilocybin, MDMA

Broad Product Capability

- 30+ dosage forms across Cannabis, Psilocybin and MDMA
- 300+ medicine brands that we white label manufacture in Australia

Scaled Commercial Platform

- 130+ customers | 800+ medication products
- Supplying Australia, Germany and the UK
- In 2026 BLS will manufacture >3 million medicines in Australia

01

Local demand for Cannabis medication set to explode

- Legislative reform to Driving laws: TAS, NT, VIC trials underway; NSW legislation being tabled EOM for cannabis
- Comparable markets have doubled following similar legislative changes reform
- Major shift towards the legal medicinal DR prescribed market

02

Our Capacity Advantage

- AU Current capacity: 5.2 million medicines (enough to more than meet total AU demand)
- Can double output immediately via additional production shifts
- UK in-country production will come on-line end of year (pricing and capacity advantage)

03

Commercial Momentum

- Increasing commercial agreements with global operators
- Selected by partners for scale, speed and reliability
- Ability to deliver in weeks vs. months — a key competitive differentiator

04

Operating Flexibility

- Rapid reallocation of production across product lines
- Ability to pivot across multiple dosage forms
- Positioned to capture evolving and emerging market demand

Our Growth Drivers & Operational Execution



GROWTH DRIVERS

- Growing patient demand and regulatory progress
- International expansion – UK, Germany, Europe
- New contract wins with new clients
- Expansion in white-label manufacturing
- Increasing domestic demand
- Innovative, high-margin dose formats (pastilles, edibles,)
- Capacity expansion and automation
- Winning more business from existing clients

EXECUTION & PROOF

- Capacity expansion
4 new clean rooms | +150% processing capacity
- Improved unit economics
White-label manufacturing, value add pharma services, economies of scale, buying power
- EBITDA margin improvement
Driven by scale, systems and automation
- Contract wins across AU & international markets
- Entry into UK, Germany & LATAM

+150%
Processing Capacity

4 New
Clean Rooms

EBITDA
Margin Growth

Global Expansion



Replicating Proven Capability

United Kingdom

GB UK Market

£850k | A\$1.7m secured

£850k (A\$1.7m) government funding secured (grant & loan)

Building GMP facility replicating Australia's proven model

Already supplying UK customers from AU – will shift to in-country manufacturing end of 2026

Germany & Europe

DE EU Market Entry

Adrex Pharma — \$6 initial orders completed October 2025 thru February 2026

Market entry secured (Adrex Pharma)

Scaling up rapidly.
Contracted \$6m in June 2025.
Delivered in October/February.

Significant uplift expected for ongoing supply

LATAM & Beyond

Central America

~A\$1m potential annual revenue

Remidose agreement (Costa Rica & Panama)

THC pastilles supply

First-mover advantage

STRATEGIC ENABLERS

Exclusive Curaleaf Partnership

Strategic global distribution channel across key markets

EU GMP Mutual Recognition Agreements

Regulatory compliance enabling direct supply into Europe


Compliant Global Supply from Australia

Enabling scalable, cost-effective manufacturing at source


CAPITAL STRUCTURE

Share price	\$0.052
Market capitalisation	\$116.5m
52-week high	\$0.060
52-week low	\$0.019

BXN Share Price Performance – 12 Months (Feb 2025 – Feb 2026)



SHAREHOLDER BREAKDOWN



All data as of 28th Feb 2026

This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company).

The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subject to change without notice and, subject only to any legal obligations to do so, Bioxyne does not have any obligation to correct or update the contents of this Presentation.

The Presentation contains certain “forward-looking statements”. The words “forecast”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice and involve known and unknown risks and certainties and other factors which are beyond the control of Bioxyne, and its directors and management, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. Recipients are cautioned not to place undue reliance on forward-looking statements. Refer to the risk factors section of this Presentation for some of the key known risks. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation.

The forward-looking statements are based on information available to Bioxyne as at the date of this Presentation. Circumstances may change and the contents of this Presentation may become outdated as a result. Except as required by law or regulation, none of Bioxyne, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

No party other than Bioxyne has authorised or caused the issue, lodgement, submission, dispatch or provision at the end of this Presentation, or takes any responsibility for, or makes or purports to make any statements, representations or undertakings in this Presentation. To the maximum extent permitted by law, Bioxyne (including its subsidiaries, related bodies corporate, shareholders, affiliates, advisers and agents):

- disclaims all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation;
- disclaims any obligations or undertaking to release any updates or revision to the information in this Presentation to reflect any change in expectations or assumptions; and
- does not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this Presentation or the likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement.



Not An Offer

This Presentation is not a prospectus, product disclosure document or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and should not be considered as, an offer, solicitation, inducement, recommendation or an invitation to acquire securities in Bioxyne or any other financial products, and neither this document nor any of its contents will form the basis of any contract or commitment.

This Presentation may not be distributed to any person in any country outside Australia except to the extent permitted under applicable laws. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice on such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not Financial Product Advice

This Presentation is not financial product, investment advice or a recommendation to acquire Bioxyne securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including, but not limited to, the assumptions, uncertainty and contingencies which may affect future operations of Bioxyne and the impact that different future outcomes may have on Bioxyne. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Bioxyne is not licensed to provide financial product advice in respect of its securities or any other financial products.





Bioxyne

Sam Watson

Managing Director

sam@breathelifesciences.com

Jason Hine

Executive Director/Chief Operations Officer

jason@breathelifesciences.com

Melissa Tempra

Media and Investor Relations

melissa@nwrcommunications.com.au